BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 8355041)

  • 1. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
    Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
    J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
    Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
    Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
    Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):220-4. PubMed ID: 1557652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
    Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
    J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.
    Wadler S; Lembersky B; Atkins M; Kirkwood J; Petrelli N
    J Clin Oncol; 1991 Oct; 9(10):1806-10. PubMed ID: 1919631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
    Köhne CH; Wilke H; Hiddemann W; Bokemeyer C; Lohrmann HP; Bodenstein H; Preiss J; Rauschecker H; Hill H; Kaufer C; Fischer JT; Ohl U; Urbanitz D; Balleisen L; Schmoll HJ
    Oncology; 1997; 54(2):96-101. PubMed ID: 9075778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
    Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
    Bukowski RM; Inoshita G; Yalavarthi P; Murthy S; Gibson V; Budd GT; Sergi JS; Bauer L; Prestifilippo J
    Cancer; 1992 Feb; 69(4):889-92. PubMed ID: 1735080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
    Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
    Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH
    Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.